Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows ...

U.S. public health authorities have skirted normal procedures and announced two major policy changes that will likely reduce ...

With U.S. recommendations for COVID-19 vaccines in flux, a leading member of the CDC's COVID vaccine advisory group is ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...